- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00293397
Chemoembolization Using Doxorubicin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Treatment of Patients With Hepatocellular Carcinoma Using Drug-Eluting Bead Embolization
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing. Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping chemotherapy drugs near the tumor.
PURPOSE: This clinical trial is studying how well chemoembolization using doxorubicin works in treating patients with liver cancer that cannot be removed by surgery.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
- Determine, preliminarily, the feasibility of chemoembolization with GelSpheres™ beads mixed with doxorubicin hydrochloride in patients with unresectable hepatocellular carcinoma.
OUTLINE: This is a pilot study.
Patients undergo catheterization of the hepatic artery followed by chemoembolization comprising an infusion of GelSpheres™ beads mixed with doxorubicin hydrochloride into the target hepatic artery. Patients may receive up to 3 chemoembolization treatments.
After completion of study treatment, patients are followed at 1 month, every 2 months for 1 year, and then every 3 months during year 2.
PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21231-2410
- Sidney kimmel comprehensive cancer center at johns hopkins
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Diagnosis of hepatocellular carcinoma (HCC) according to the European Association for the Study of Liver (EASL) disease diagnostic criteria AND the Okuda staging classification
No advanced disease, as defined by any of the following:
Barcelona Clinic Liver Cancer (BCLC) class C disease, as defined by the following:
- Vascular invasion, including segmental portal obstruction
- Extrahepatic spread
- Cancer-related symptoms (PST of 1-2)
BCLC class D disease, as defined by the following:
- Okuda stage III disease
- World Health Organization (WHO) performance status 3 or 4
- Diffuse HCC, defined as massive ill-defined tumor involvement
- Child-Pugh Class C
- Not eligible for radical therapies (e.g., resection, liver transplantation, or percutaneous therapies)
No significant liver decompensation
Preserved liver function (Child-Pugh class A-B)
- No ascites (trace ascites allowed)
- No other active primary tumor
- Arteries supplying the lesion must be large enough to accept GelSpheres™ beads
PATIENT CHARACTERISTICS:
- Bilirubin ≤ 3 mg/dL
- Albumin > 2.0 g/dL
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 times the upper limit of normal (ULN)
- Alkaline phosphatase ≤ 5 times the upper limit of normal (ULN)
- No active gastrointestinal bleeding
- No encephalopathy
No contraindication to hepatic embolization procedures, as indicated by any of the following:
- Porto-systemic shunt
- Hepatofugal blood flow
- Platelet count < 50,000/mm^3
- International normalized ratio (INR) ≥ 1.8
- Partial thromboplastin time (PTT) ≥ 39 seconds
- Renal failure
- Severe atheromatosis
No contraindication to doxorubicin hydrochloride administration, as indicated by any of the following:
- Bilirubin > 5 mg/dL
- White blood cell (WBC) < 1,500/mm^3
- Ejection fraction < 50% by isotopic ventriculography or echocardiography
- Not pregnant
- No known allergy to contrast media
- No intolerance to occlusion procedures
No vascular anatomy or bleeding that would preclude catheter placement or emboli injection, as indicated by any of the following:
- Active or risk of hemorrhage
- Patent extra-to-intracranial anastomoses or shunts
- End arteries leading directly to the cranial nerves
- Feeding arteries smaller than distal branches from which they emerge
- Collateral vessel pathways that would potentially endanger normal territories during embolization
PRIOR CONCURRENT THERAPY:
- No prior anticancer therapy for HCC
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Drug-eluting bead transarterial chemoembolization (DEB-TACE)
Patients undergo DEB-TACE procedures utilizing LC Beads, polyvinyl alcohol microspheres with diameters of 100-300um or 300-500um, which are loaded with 100mg of doxorubicin hydrochloride and mixed with an equal volume of nonionic contrast media.
|
Doxorubicin eluting beads
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety
Time Frame: 1 month
|
Safety was assessed using the CTCAE v 3.0 criteria, reported are the number of participants that experienced at least 1 event that was grade 2 (moderate) or higher.
|
1 month
|
Safety
Time Frame: 6 months
|
Safety was assessed using the CTCAE v 3.0 criteria, reported are the number of participants that experienced at least 1 event that was grade 2 (moderate) or higher.
|
6 months
|
Efficacy - Tumor Response by the European Association for the Study of the Liver (EASL) Criteria
Time Frame: 1 month
|
Efficacy as assessed by radiographic tumor response using EASL criteria at baseline and at 1 month post-TACE Complete Response (CR): Achieving 100% tumor necrosis of targeted lesions Partial Response (PR): Demonstrating greater than 50% tumor necrosis in targeted lesions Progressive Disease (PD): Reappearance of or increased tumor enhancement greater than 25% in targeted lesions Stable Disease (SD): Not meeting requirements for CR or PR and not demonstrating evidence of progression in targeted lesions. |
1 month
|
Efficacy - Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST)
Time Frame: 1 month
|
Efficacy as assessed by radiographic tumor response using RECIST criteria at baseline, 1 month post treatment. Complete Response (CR): Disappearance of all lesions targeted by therapy Partial Response (PR): At least 30% decrease in the sum of longest diameter (LD) of lesions targeted by therapy Progressive Disease (PD): At least 20% increase in sum of LD of lesions targeted by therapy Stable Disease (SD): Neither sufficient shrinkage for PR nor sufficient increase for PD. |
1 month
|
Efficacy - Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST)
Time Frame: 6 months
|
Efficacy as assessed by radiographic tumor response using RECIST criteria at baseline, and at 6 months post treatment. Complete Response (CR): Disappearance of all lesions targeted by therapy Partial Response (PR): At least 30% decrease in the sum of longest diameter (LD) of lesions targeted by therapy Progressive Disease (PD): At least 20% increase in sum of LD of lesions targeted by therapy Stable Disease (SD): Neither sufficient shrinkage for PR nor sufficient increase for PD. |
6 months
|
Efficacy - Overall Survival
Time Frame: 1 Year
|
Presented are the counts of patients that have survived up to 1 year.
|
1 Year
|
Efficacy - Overall Survival
Time Frame: 2 Years
|
Presented are the counts of patients that have survived up to 2 years.
|
2 Years
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Digestive System Neoplasms
- Liver Diseases
- Liver Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Doxorubicin
- Liposomal doxorubicin
Other Study ID Numbers
- CDR0000456493
- P30CA006973 (U.S. NIH Grant/Contract)
- JHOC-J0516
- HOC-05042805
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Cancer
-
Slawa CwajnaNova Scotia Health AuthorityWithdrawnPrimary Liver Cancer | Metastatic Liver CancerCanada
-
Duke UniversityCompletedPrimary Liver Cancer | Metastatic Liver Cancer From Any Cancer SiteUnited States
-
University of HawaiiGlaxoSmithKlineRecruitingAdvanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Adult Primary Liver CancerUnited States
-
Célia TurcoCompletedPrimary Liver Cancer | Liver Metastases | Secondary Liver CancerFrance
-
University of CincinnatiActive, not recruitingLiver Metastases | Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver CancerUnited States
-
Lisa H. Butterfield, Ph.D.National Cancer Institute (NCI)TerminatedHepatocellular Carcinoma | Liver Cancer | Cancer of Liver | Hepatoma | Hepatocellular Cancer | Hepatic Cancer | Liver Cell Carcinoma | Cancer, Hepatocellular | Liver Cancer, Adult | Liver Cell Carcinoma, Adult | Cancer of the Liver | Neoplasms, Liver | Hepatic Neoplasms | Neoplasms, HepaticUnited States
-
Radboud University Medical CenterTerumo Medical CorporationCompletedPrimary Liver Cancer | Liver Cancer | Liver Metastasis Colon CancerNetherlands
-
Cardiovascular and Interventional Radiological...RecruitingPrimary Liver Cancer | Secondary Liver CancerGermany
-
Shanghai Huihe Medical Technology Co., LtdEnrolling by invitation
-
Burzynski Research InstituteTerminatedPrimary Liver CancerUnited States
Clinical Trials on Drug-eluting beads loaded with doxorubicin hydrochloride
-
Heidelberg UniversityUniversity Hospital Tuebingen; SLK Kliniken Heilbronn GmbHUnknownStage IV Melanoma Patients With Unresectable Liver MetastasesGermany
-
Fudan UniversityNot yet recruitingColorectal Cancer | Liver MetastasesChina
-
Ningbo Medical Center Lihuili HospitalRecruiting
-
Brno University HospitalMasaryk University; Masaryk Memorial Cancer InstituteCompletedHepatocellular Carcinoma | Hepatocellular Carcinoma by BCLC Stage
-
Robert C. MartinM.D. Anderson Cancer Center; Thomas Jefferson University; University of LouisvilleCompletedLC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma (DEBDOX)Stage IV MelanomaUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...B. Braun Medical B.V.Unknown
-
Tianjin Medical University Cancer Institute and...Not yet recruiting
-
The Central Hospital of Lishui CityNot yet recruitingCarcinoma | Small Cell Lung CancerChina
-
King Faisal Specialist Hospital & Research CenterUnknownHepatocellular CarcinomaSaudi Arabia
-
Sahlgrenska University Hospital, SwedenUppsala University; The Swedish Research Council; Swedish Heart Lung Foundation; The Swedish National Registry for Vascular SurgeryActive, not recruitingPeripheral Arterial Disease | Intermittent Claudication | Critical Limb IschemiaSweden